Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.
about
Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virusLewis Acid Mediated Nazarov Cyclization as a Convergent and Enantioselective Entry to C-nor-D-homo-Steroids.Patent highlights August-September 2017.
P2860
Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeting human respiratory sy ...... bit in vivo viral replication.
@en
type
label
Targeting human respiratory sy ...... bit in vivo viral replication.
@en
prefLabel
Targeting human respiratory sy ...... bit in vivo viral replication.
@en
P2093
P2860
P50
P356
P1433
P1476
Targeting human respiratory sy ...... bit in vivo viral replication.
@en
P2093
D-C Sharma
L Johansen
M von Itzstein
R Altmeyer
P2860
P2888
P356
10.1038/SREP25806
P407
P577
2016-05-19T00:00:00Z
P6179
1002806338